#1

https://www.nature.com/articles/s43856-025-00904-9

Rapamycin is not detectable in the CSF before or after treatment, but several Alzheimer’s disease and inflammatory biomarkers increase after treatment. Our results highlight the need to better understand the biological effects and clinical impact of repurposing rapamycin for Alzheimer’s disease.

I wish they also had a study with everolimus which seems to cross the blood-brain barrier.

#2

2 posts were merged into an existing topic: Rapamycin and Alzheimer Disease: a Hypothesis for the Effective use of Rapamycin

#4